Drug Profile
Sodium oxybate - CT Laboratories
Alternative Names: Alcover; SMO immediate release formulation - D&A PharmaLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator CT Laboratories
- Developer CT Laboratories; G.L. Pharma
- Class Butyric acids; Hydroxybutyrates; Sleep disorder therapies; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alcoholism
Most Recent Events
- 20 Oct 2020 CT Laboratories initiates enrolment in the phase-III OXYLIFE trial for Alcoholism in Italy (EudraCT2019-001834-33)
- 03 Jul 2019 Chemical structure information added
- 22 Dec 1999 Registered & Launched for Alcoholism in Austria (PO)